← Back to feedRead original →
VERIFIEDET Stocks·positive
Stocks to buy in 2026 for long term: Dr Lal PathLabs, IDFC First Bank among 5 stocks that could give 10-30% return
AI Summary
- ·Nuvama has reiterated its 'Buy' rating on Dr Lal PathLabs.
- ·The target price for Dr Lal PathLabs has been raised to Rs 2,140 from Rs 1,900.
- ·This implies a potential upside of 21% from the current market price of Rs 1,756.